Adjuvant chemotherapy in stage I breast cancer. More harm than benefit.

PubWeight™: 0.85‹?›

🔗 View Article (PMC 2379875)

Published in Can Fam Physician on October 01, 1993

Authors

C B Mueller1

Author Affiliations

1: McMaster University, Hamilton, Ont.

Articles citing this

Debate on using adjuvant chemotherapy. Can Fam Physician (1994) 0.75

Articles cited by this

Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med (1976) 9.68

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med (1989) 6.24

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med (1989) 1.99

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67

Adjuvant therapy of node-negative breast cancer. N Engl J Med (1989) 1.43

Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol (1986) 1.28

Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet (1984) 1.18

Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med (1989) 1.06

Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer (1986) 0.95

Stage II breast cancer is not simply a late stage I. Surgery (1988) 0.92

Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081. Cancer (1988) 0.89